RxDoctor Payments Data

Niketa Dani, MD

Internal Medicine · Fenton, MINPI 1649272477

Payments from drug & device makers

$6,351in general payments, 2019–2025

Across 330 payments — averaging $19.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$972
  • GSK$756
  • Novo Nordisk$569
  • AbbVie$454
  • Amgen$413
  • Lilly USA, LLC$354
  • plus $3K from 39 others

What the payments were for

  • Food & beverage$6,323100%
  • Education$280%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,351 in reported general payments places this provider in the 90th percentile of 4,567 internal medicine providers in Michigan.

See all internal medicine providers in Michigan

Medicare billing

Part B allowed, 2024
$49,489
Medicare patients
127
Services billed
803

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
TrulicityDulaglutide32$51,751
Trelegy ElliptaFluticasone/Umeclidin/Vilanter42$48,691
EliquisApixaban26$37,849
JardianceEmpagliflozin24$27,065
RybelsusSemaglutide11$25,868
FarxigaDapagliflozin Propanediol11$11,414
MyrbetriqMirabegron13$8,334
ShingrixVaricella-Zoster Ge/As01b/Pf35$7,817
Qvar RedihalerBeclomethasone Dipropionate12$5,746
Fluticasone-SalmeterolFluticasone Propion/Salmeterol13$3,621
Lantus SolostarInsulin Glargine,hum.Rec.Anlog26$3,394
Atorvastatin Calcium221$2,930
Adacel TdapDiph,pertuss(Acell),tet Vac/Pf25$1,859
Levothyroxine Sodium171$1,748
Losartan Potassium116$1,595

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Shingrix$756$56,50877 claims
Lilly USA, LLCTrulicity$354$51,75132 claims
PfizerEliquis$283$37,84926 claims
Boehringer IngelheimJardiance$130$27,06524 claims
Novo NordiskRybelsus$569$25,86811 claims
AstraZenecaFarxiga$972$11,41411 claims
Astellas Pharma US IncMyrbetriq$27$8,33413 claims
Teva Pharmaceuticals USA, Inc.Qvar Redihaler$39$5,74612 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 4,567 internal medicine providers in Michigan.

Other internal medicine in Fenton

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →